Observational Study of Docetaxel Exposure in Metastatic Prostate Cancer Patients
Status:
Unknown status
Trial end date:
2019-12-01
Target enrollment:
Participant gender:
Summary
In this observational study, blood samples for pharmacokinetic (PK) testing will be collected
from subjects with metastatic prostate cancer during their treatment with docetaxel. Plasma
levels of docetaxel will be determined, and the subjects docetaxel exposure levels,
determined as an area under the curve (AUC), will be retrospectively correlated with reports
of toxicity, tumor response, quality of life, time to disease progression and overall
survival to provide guidance on what the appropriate target range for docetaxel exposure
should be for metastatic prostate cancer subjects receiving docetaxel therapy for their
disease.